JP7455144B2 - トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 - Google Patents

トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 Download PDF

Info

Publication number
JP7455144B2
JP7455144B2 JP2021564297A JP2021564297A JP7455144B2 JP 7455144 B2 JP7455144 B2 JP 7455144B2 JP 2021564297 A JP2021564297 A JP 2021564297A JP 2021564297 A JP2021564297 A JP 2021564297A JP 7455144 B2 JP7455144 B2 JP 7455144B2
Authority
JP
Japan
Prior art keywords
dry powder
powder composition
palmityl
treprostinil
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530637A (ja
JP2022530637A5 (OSRAM
Inventor
ジュ ドゥ，
アダム プラント，
ウラジミール マリニン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of JP2022530637A publication Critical patent/JP2022530637A/ja
Publication of JP2022530637A5 publication Critical patent/JP2022530637A5/ja
Priority to JP2024037977A priority Critical patent/JP7732017B2/ja
Application granted granted Critical
Publication of JP7455144B2 publication Critical patent/JP7455144B2/ja
Priority to JP2025137209A priority patent/JP2025164854A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021564297A 2019-04-29 2020-04-28 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 Active JP7455144B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024037977A JP7732017B2 (ja) 2019-04-29 2024-03-12 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2025137209A JP2025164854A (ja) 2019-04-29 2025-08-20 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840186P 2019-04-29 2019-04-29
US62/840,186 2019-04-29
PCT/US2020/030282 WO2020223237A1 (en) 2019-04-29 2020-04-28 Dry powder compositions of treprostinil prodrugs and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024037977A Division JP7732017B2 (ja) 2019-04-29 2024-03-12 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022530637A JP2022530637A (ja) 2022-06-30
JP2022530637A5 JP2022530637A5 (OSRAM) 2023-03-28
JP7455144B2 true JP7455144B2 (ja) 2024-03-25

Family

ID=72917621

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021564297A Active JP7455144B2 (ja) 2019-04-29 2020-04-28 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2024037977A Active JP7732017B2 (ja) 2019-04-29 2024-03-12 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2025137209A Pending JP2025164854A (ja) 2019-04-29 2025-08-20 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024037977A Active JP7732017B2 (ja) 2019-04-29 2024-03-12 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2025137209A Pending JP2025164854A (ja) 2019-04-29 2025-08-20 トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Country Status (10)

Country Link
US (4) US11458098B2 (OSRAM)
EP (1) EP3962472A4 (OSRAM)
JP (3) JP7455144B2 (OSRAM)
KR (1) KR20220002600A (OSRAM)
CN (2) CN114072136B (OSRAM)
AU (2) AU2020265576B2 (OSRAM)
BR (1) BR112021021775A2 (OSRAM)
CA (1) CA3138530A1 (OSRAM)
MX (2) MX2021013329A (OSRAM)
WO (1) WO2020223237A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4236934A4 (en) * 2020-10-28 2024-10-02 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
AU2022229367A1 (en) * 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
KR20250169548A (ko) * 2023-03-17 2025-12-03 인스메드 인코포레이티드 분무 건조 트레프로스티닐 제형
WO2025096521A1 (en) 2023-10-30 2025-05-08 Insmed Incorporated Medicament delivery device, cover, and methods of medicament delivery
WO2025147662A1 (en) * 2024-01-04 2025-07-10 Insmed Incorporated Methods of treatment using dry powder compositions of treprostinil prodrugs
WO2025199537A1 (en) * 2024-03-22 2025-09-25 Wbx Pharma, Inc. Inhaled hedgehog inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540734A (ja) 2013-10-25 2016-12-28 インスメッド， インコーポレイテッド プロスタサイクリン化合物、組成物およびその使用方法
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
DE2947526A1 (de) 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge
US4668814A (en) 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
JPS61289034A (ja) 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
US4837342A (en) 1986-02-28 1989-06-06 Sagami Chemical Research Center Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
IT1240750B (it) 1990-04-12 1993-12-17 Chiesi Farma Spa Dispositivo per la somministrazione di sostanze medicamentose in polvere
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
SE9302550D0 (sv) 1993-07-30 1993-07-30 Ernst Hoerlin Powder inhaler
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
FI95441C (fi) 1994-05-31 1996-02-12 Leiras Oy Inhalointilaitteen lääkeainekammio
FR2725626A1 (fr) 1994-10-18 1996-04-19 Sofab Dispositif pour l'inhalation de produits en poudre
SE9404439D0 (sv) 1994-12-21 1994-12-21 Astra Ab Inhalation device
ES2216418T3 (es) 1995-12-07 2004-10-16 Jago Research Ag Boquilla para un inhalador para la administracion de varias dosis de un polvo seco farmacologico.
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
US6026809A (en) 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
AU5806998A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
PT101988B (pt) 1997-04-04 2004-02-27 Hovione Farmaciencia Sa Sistema de orientacao e posicionamento de um objecto
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
KR100638684B1 (ko) 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
AU742250B2 (en) 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
GB9805102D0 (en) 1998-03-10 1998-05-06 Ciba Geigy Ag Device
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000006120A1 (en) 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
JP4416325B2 (ja) 1998-08-25 2010-02-17 アルカーメス，インコーポレイテッド 安定な噴霧乾燥タンパク質製剤
US6265495B1 (en) 1998-09-22 2001-07-24 Nippon Shokubai Co., Ltd. Method for production of esterified product
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
EP1164846A1 (en) 1999-03-31 2002-01-02 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
PL201275B1 (pl) 2000-03-10 2009-03-31 Univ North Carolina Inhalator suchego proszku
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20030108512A1 (en) 2001-12-10 2003-06-12 Robert Shorr Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
WO2004012680A2 (en) 2002-08-06 2004-02-12 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
CN1791386A (zh) 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
ATE341312T1 (de) 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
ES2670872T3 (es) 2003-05-22 2018-06-01 United Therapeutics Corporation Polimorfo de una sal de dietanolamina de treprostinil
ES2289221T3 (es) 2003-10-06 2008-02-01 BANG & OLUFSEN MEDICOM A/S Inhalador.
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
JP4906514B2 (ja) 2003-12-16 2012-03-28 ユナイテッド セラピューティクス コーポレイション 腎臓機能改善のためのトレプロスチニルの用途
US8765813B2 (en) 2003-12-16 2014-07-01 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
CA2562614C (en) 2004-04-12 2013-09-17 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
GB0416328D0 (en) * 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
EP1796653A2 (en) 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
WO2006043655A1 (ja) 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
JP5797376B2 (ja) 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US20080280986A1 (en) 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
EP2711024B1 (en) 2007-09-07 2019-03-06 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
KR20110010753A (ko) 2008-05-08 2011-02-07 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐 일수화물
WO2009152160A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
US20110294815A1 (en) 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
WO2010039531A1 (en) 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Therapeutic compounds
US20120177693A1 (en) 2008-09-25 2012-07-12 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
AU2010220061A1 (en) 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
EP2427054A4 (en) 2009-05-07 2014-01-15 United Therapeutics Corp SOLID COMPOSITIONS BASED ON PROSTACYCLINE ANALOGS
US8519178B2 (en) 2009-06-22 2013-08-27 Johnson Matthey Public Limited Company Method for the purification of prostaglandins
US20120270934A1 (en) 2009-07-03 2012-10-25 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US20120184622A1 (en) 2009-08-07 2012-07-19 Scipharm Sarl Composition for the treatment of cystic fibrosis
US20120232034A1 (en) 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
CN101669904B (zh) 2009-09-29 2011-06-22 北京中海康医药科技发展有限公司 一种依前列醇脂质纳米粒及制备方法
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
US8481782B2 (en) 2010-06-03 2013-07-09 United Therapeutics Corporation Treprostinil production
WO2011159693A2 (en) 2010-06-15 2011-12-22 United Therapeutics Corporation Oral treatment of digital ischemic lesions
US20120010159A1 (en) 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
JP5780775B2 (ja) 2011-02-18 2015-09-16 株式会社Ｌｔｔバイオファーマ プロスタグランジンｉ２誘導体を含有するナノ粒子
KR101454571B1 (ko) 2011-03-02 2014-10-23 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐 생산을 위한 중간체 합성
JP5850915B2 (ja) 2011-03-14 2016-02-03 国立大学法人北海道大学 肺送達のためのベクター、導入剤及び使用
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
WO2013024049A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Protein carrier-linked prodrugs
AU2012296949B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
EP2741781A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
US9872864B2 (en) 2011-08-12 2018-01-23 Ascendis Pharma A/S Sustained release composition of prostacyclin
US8524939B2 (en) 2011-08-24 2013-09-03 Chirogate International Inc. Intermediates for the synthesis of benzindene prostaglandins and preparations thereof
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
LT2674413T (lt) 2012-06-15 2017-09-25 Scipharm Sąrl Treprostinilo ir jo darinių gavimo būdas
ES2869701T3 (es) 2012-08-01 2021-10-25 United Therapeutics Corp Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina
IN2015DN00934A (OSRAM) 2012-08-01 2015-06-12 United Therapeutics Corp
JP6357481B2 (ja) 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
AU2014205557B2 (en) 2013-01-09 2017-08-10 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
CA3125504C (en) 2013-03-14 2023-10-24 United Therapeutics Corporation Solid forms of treprostinil
KR20150128903A (ko) 2013-03-15 2015-11-18 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 염
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
EP2991639A4 (en) 2013-04-30 2016-11-30 United Therapeutics Corp PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE
WO2014203278A2 (en) 2013-06-19 2014-12-24 Msn Laboratories Private Limited NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID
WO2015054574A1 (en) * 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2016176555A1 (en) 2015-04-29 2016-11-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
AU2016291228B2 (en) * 2015-07-09 2020-04-09 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
WO2017223400A1 (en) 2016-06-24 2017-12-28 Insmed Incorporated Prostacyclin compounds and compositions for treating sarcoidosis
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
JP2021527058A (ja) 2018-06-07 2021-10-11 マンカインド コーポレイション 吸入のための組成物および方法
EP3673895A1 (en) 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
WO2021195328A1 (en) 2020-03-25 2021-09-30 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof
EP4236934A4 (en) 2020-10-28 2024-10-02 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
CN114652704A (zh) 2022-04-29 2022-06-24 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540734A (ja) 2013-10-25 2016-12-28 インスメッド， インコーポレイテッド プロスタサイクリン化合物、組成物およびその使用方法
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Drug Delivery，2014年，21(6)，pp.397-405
Drug Res，2018年，68，pp.605-614
European Respiratory Journal，2017年，50，PA2377
International Journal of Pharmaceutics，2016年，506，pp.174-183
J Pharmacol Exp Ther，2017年，363，pp.348-357
Journal of Drug Delivery Science and Technology，2019年，49，pp.97-106
Journal of Drug Delivery，2018年，Volume 2018，Article ID 5635010 (19 pages)
Plumonary Pharmacology & Therapeutics，2018年，49，pp.104-111

Also Published As

Publication number Publication date
JP2022530637A (ja) 2022-06-30
JP2024069403A (ja) 2024-05-21
US20240050373A1 (en) 2024-02-15
BR112021021775A2 (pt) 2022-01-04
CN114072136B (zh) 2024-11-29
CN114072136A (zh) 2022-02-18
JP7732017B2 (ja) 2025-09-01
WO2020223237A1 (en) 2020-11-05
JP2025164854A (ja) 2025-10-30
US12201725B2 (en) 2025-01-21
AU2020265576B2 (en) 2025-09-18
US20200338005A1 (en) 2020-10-29
US11759425B2 (en) 2023-09-19
EP3962472A4 (en) 2023-01-25
US20250177306A1 (en) 2025-06-05
AU2025271236A1 (en) 2025-12-18
EP3962472A1 (en) 2022-03-09
MX2024001929A (es) 2024-03-04
MX2021013329A (es) 2022-03-17
KR20220002600A (ko) 2022-01-06
AU2020265576A1 (en) 2021-11-25
CN119632930A (zh) 2025-03-18
CA3138530A1 (en) 2020-11-05
US20220409537A1 (en) 2022-12-29
US11458098B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7732017B2 (ja) トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP7857292B2 (ja) トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
WO2005092301A1 (en) Insulin highly respirable microparticles
JP2023519199A (ja) トレプロスチニルプロドラッグの医薬製剤及びその使用方法
JP2017533212A (ja) 肺送達用ラパマイシン粉末
WO2022170081A1 (en) Antiarrhythmic formulation
BR122024026324A2 (pt) Composição de pó seco, uso de uma composição de pó seco e sistema
CA3268243A1 (en) CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
JP2026509493A (ja) 噴霧乾燥トレプロスチニル製剤
JP2025513460A (ja) 粉末吸入による医薬品の送達
WO2025147662A1 (en) Methods of treatment using dry powder compositions of treprostinil prodrugs
CA3005290C (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
HK40118752A (zh) 用於施用磷酸二酯酶-4抑制剂的胶囊吸入器
CN120837461A (zh) 一种尼达尼布吸入粉雾剂及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240312

R150 Certificate of patent or registration of utility model

Ref document number: 7455144

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150